Sandoz to Acquire Cimerli Business from Coherus for $170 Million
2024年1月22日 - 3:59PM
Dow Jones News
By David Sachs
Sandoz will buy vision-impairment drug Cimerli from Coherus
BioSciences for $170 million.
The Swiss pharmaceutical company said Monday that the purchase
of the U.S. company's medication includes a biologics license,
product inventory, and ophthalmology sales, as well as access to
proprietary commercial software.
The medication, which treats serious eye conditions including
macular degeneration, is interchangeable with Lucentis, a drug
developed by Genentech. Sandoz expects to close the deal in the
second half of this year.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
January 22, 2024 01:44 ET (06:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
過去 株価チャート
から 3 2024 まで 4 2024
Novartis (NYSE:NVS)
過去 株価チャート
から 4 2023 まで 4 2024
